Anika Therapeutics | ANIK - Ebitda


Anika Therapeutics reported $4.54M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
Agenus USD -10.11M 19.02M Mar/2025
Agios Pharmaceuticals USD -109.2M 540K Jun/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
Halozyme Therapeutics USD 336.16M 7.34M Sep/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -80.97M 93.7M Sep/2026
Integra LifeSciences USD 79.79M 1.37M Sep/2026
Intrexon USD -24.7M 2.92M Jun/2024
J&J USD 8.99B 721M Jun/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 74.27M 88.56M Jun/2026
MacroGenics USD -64.54M 34.34M Jun/2026
Merit Medical Systems USD 103.93M 461K Sep/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Sanofi EUR 5.79B 2.1B Sep/2026
Smith & Nephew USD 796M 139M Dec/2025
Stryker USD 1.83B 102M Sep/2026
Veracyte USD 41.24M 2.72M Sep/2026
Xencor USD 25.1M 59.73M Sep/2026
Zimmer Biomet Holdings USD 634.8M 195.7M Sep/2026